[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @chavarriagaj Julian Chavarriaga Julian Chavarriaga posts on X about novo, $fro, rana, db the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::159184453/interactions)  - X Week XXXXX +8,451% - X Month XXXXX +509% - X Months XXXXXX +1,472% ### Mentions: X [#](/creator/twitter::159184453/posts_active)  - X Week X -XX% - X Month XX +1,200% - X Months XX +2,200% ### Followers: XXX [#](/creator/twitter::159184453/followers)  - X Week XXX +7.30% - X Month XXX +13% - X Months XXX +66% ### CreatorRank: XXXXXXX [#](/creator/twitter::159184453/influencer_rank)  ### Social Influence [#](/creator/twitter::159184453/influence) --- **Social topic influence** [novo](/topic/novo) 8.33%, [$fro](/topic/$fro) 8.33%, [rana](/topic/rana) 8.33%, [db](/topic/db) 8.33%, [trend in](/topic/trend-in) 8.33%, [mets](/topic/mets) 8.33%, [pts](/topic/pts) 8.33%, [alpaca](/topic/alpaca) 8.33%, [vas](/topic/vas) 8.33%, [aa](/topic/aa) XXXX% **Top accounts mentioned or mentioned by** [@urotoday](/creator/undefined) [@asco](/creator/undefined) [@myesmo](/creator/undefined) [@ohsuknight](/creator/undefined) [@uclnews](/creator/undefined) [@aarmstrong](/creator/undefined) [@petegodolphin](/creator/undefined) [@uhn](/creator/undefined) [@drathkopf](/creator/undefined) [@jitenjaipuria](/creator/undefined) **Top assets mentioned** [Frontline Ltd. (FRO)](/topic/$fro) ### Top Social Posts [#](/creator/twitter::159184453/posts) --- Top posts by engagements in the last XX hours "#ESMO25 @petegodolphin presents updated STOPCAP meta-analysis on prostate RT in de novo mHSPC 📊 X RCTs pooled (HORRAD STAMPEDE PEACE-1): 🧍♂ 59y FU 3.25.3y median OS 📌 RT + SoC vs SoC alone 🔹 OS: HR XXXX (95% CI 0.841.00; p=0.058) 🔹 PFS: HR XXXX (95% CI 0.810.95; p=0.002) ✅ 🔹 Subgroups: X bone mets: PFS HR 0.79; OS HR XXXX X mets: No OS/PFS benefit Low-volume: OS HR XXXX (8% 5y OS) High-volume: No benefit Docetaxel use No interaction (p=0.87) @Urotoday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979162741308035582) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-17T12:29Z XXX followers, 2781 engagements "#ESMO25 Dr. Rana McKay explores LAG-3 as biomarker in frontline RCC ICI 🧬 n=566 from Tempus DB stratified by LAG-3 RNA (Q1Q4) 🔹 LAG-3 immune cell infiltration 🔹 Liver mets in Q4 but no clear trend in ORR or OS across quartiles 🧪 LAG-3 alone may not predict ICI benefit 📢 Still adds to growing evidence of LAG-3s immunologic relevance @myESMO @UroToday" [X Link](https://x.com/chavarriagaj/status/1979800632815968618) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-19T06:43Z XXX followers, XXX engagements "#ESMO25 Dr. Srikala Sridhar @UHN presents phase X ALPACA trial of avelumab in advanced penile cancer: 🌍 Rare & aggressive tumor (38K/yr); no standard 2L tx options 💉 ORR XX% mDoR XX mo durable responses in a subset of pts ⛔ Fairly unwell pts: XXX% visceral mets XX% ECOG X X% platinum-unfit ✅ Well-tolerated promising signal for ICI in HPV+ GU tumors 🔬 Biomarker work & early setting trials needed @UroToday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979176683639808363) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-17T13:24Z XXX followers, XXX engagements "📢 #ESMO25 @DRathkopf presents PROs from AMPLITUDE: Niraparib + AA + P in HRRm mHSPC 🧬 rPFS (HR 0.63) symptomatic progression (HR 0.50) 📊 FACT-G FACT-P EQ-5D-5L VAS scores stable across arms 🩺 Most bothersome AEs (HTN anemia) peaked early; HRQoL recovered ✅ 7685% on NIRA vs 8693% on PBO reported not at all/a little bit bothered by side effects ✅ High compliance w/ ePROs supports feasibility @UroToday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979163568575594699) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-17T12:32Z XXX followers, XXX engagements "#ESMO25 Dr. Ken Herrmann on scaling radioligand therapy: 📈 Global nuclear medicine market projected to hit $42B by 2033 Major gaps in imaging & treatment access across EU: ✔ Only 1233% of eligible mCRPC patients get PSMA PET Wait times for RLT initiation still XX weeks Potential solutions 🏥 Essens FastTrackPSMARLT cuts referraltherapy time to 4w 🧠 Initiatives like PSMA Academy & theranostics centers (UCLA ICPO) @UroToday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979882447098786112) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-19T12:08Z XXX followers, 2250 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@chavarriagaj Julian Chavarriaga
Julian Chavarriaga posts on X about novo, $fro, rana, db the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +8,451%
- X Month XXXXX +509%
- X Months XXXXXX +1,472%
Mentions: X #
- X Week X -XX%
- X Month XX +1,200%
- X Months XX +2,200%
Followers: XXX #
- X Week XXX +7.30%
- X Month XXX +13%
- X Months XXX +66%
CreatorRank: XXXXXXX #
Social Influence #
Social topic influence novo 8.33%, $fro 8.33%, rana 8.33%, db 8.33%, trend in 8.33%, mets 8.33%, pts 8.33%, alpaca 8.33%, vas 8.33%, aa XXXX%
Top accounts mentioned or mentioned by @urotoday @asco @myesmo @ohsuknight @uclnews @aarmstrong @petegodolphin @uhn @drathkopf @jitenjaipuria
Top assets mentioned Frontline Ltd. (FRO)
Top Social Posts #
Top posts by engagements in the last XX hours
"#ESMO25 @petegodolphin presents updated STOPCAP meta-analysis on prostate RT in de novo mHSPC 📊 X RCTs pooled (HORRAD STAMPEDE PEACE-1): 🧍♂ 59y FU 3.25.3y median OS 📌 RT + SoC vs SoC alone 🔹 OS: HR XXXX (95% CI 0.841.00; p=0.058) 🔹 PFS: HR XXXX (95% CI 0.810.95; p=0.002) ✅ 🔹 Subgroups: X bone mets: PFS HR 0.79; OS HR XXXX X mets: No OS/PFS benefit Low-volume: OS HR XXXX (8% 5y OS) High-volume: No benefit Docetaxel use No interaction (p=0.87) @Urotoday @myESMO"
X Link @chavarriagaj 2025-10-17T12:29Z XXX followers, 2781 engagements
"#ESMO25 Dr. Rana McKay explores LAG-3 as biomarker in frontline RCC ICI 🧬 n=566 from Tempus DB stratified by LAG-3 RNA (Q1Q4) 🔹 LAG-3 immune cell infiltration 🔹 Liver mets in Q4 but no clear trend in ORR or OS across quartiles 🧪 LAG-3 alone may not predict ICI benefit 📢 Still adds to growing evidence of LAG-3s immunologic relevance @myESMO @UroToday"
X Link @chavarriagaj 2025-10-19T06:43Z XXX followers, XXX engagements
"#ESMO25 Dr. Srikala Sridhar @UHN presents phase X ALPACA trial of avelumab in advanced penile cancer: 🌍 Rare & aggressive tumor (38K/yr); no standard 2L tx options 💉 ORR XX% mDoR XX mo durable responses in a subset of pts ⛔ Fairly unwell pts: XXX% visceral mets XX% ECOG X X% platinum-unfit ✅ Well-tolerated promising signal for ICI in HPV+ GU tumors 🔬 Biomarker work & early setting trials needed @UroToday @myESMO"
X Link @chavarriagaj 2025-10-17T13:24Z XXX followers, XXX engagements
"📢 #ESMO25 @DRathkopf presents PROs from AMPLITUDE: Niraparib + AA + P in HRRm mHSPC 🧬 rPFS (HR 0.63) symptomatic progression (HR 0.50) 📊 FACT-G FACT-P EQ-5D-5L VAS scores stable across arms 🩺 Most bothersome AEs (HTN anemia) peaked early; HRQoL recovered ✅ 7685% on NIRA vs 8693% on PBO reported not at all/a little bit bothered by side effects ✅ High compliance w/ ePROs supports feasibility @UroToday @myESMO"
X Link @chavarriagaj 2025-10-17T12:32Z XXX followers, XXX engagements
"#ESMO25 Dr. Ken Herrmann on scaling radioligand therapy: 📈 Global nuclear medicine market projected to hit $42B by 2033 Major gaps in imaging & treatment access across EU: ✔ Only 1233% of eligible mCRPC patients get PSMA PET Wait times for RLT initiation still XX weeks Potential solutions 🏥 Essens FastTrackPSMARLT cuts referraltherapy time to 4w 🧠 Initiatives like PSMA Academy & theranostics centers (UCLA ICPO) @UroToday @myESMO"
X Link @chavarriagaj 2025-10-19T12:08Z XXX followers, 2250 engagements